GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aytu BioPharma Inc (NAS:AYTU) » Definitions » Tangible Book per Share

Aytu BioPharma (Aytu BioPharma) Tangible Book per Share : $-4.11 (As of Dec. 2023)


View and export this data going back to 2008. Start your Free Trial

What is Aytu BioPharma Tangible Book per Share?

Tangible book value per share is calculated as the total tangible equity divided by Shares Outstanding (EOP). Total tangible equity is calculated as the Total Stockholders Equity minus Preferred Stock minus Intangible Assets. Aytu BioPharma's tangible book value per share for the quarter that ended in Dec. 2023 was $-4.11.

Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.


Aytu BioPharma Tangible Book per Share Historical Data

The historical data trend for Aytu BioPharma's Tangible Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aytu BioPharma Tangible Book per Share Chart

Aytu BioPharma Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Tangible Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -136.79 28.72 -9.97 -13.65 -3.56

Aytu BioPharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Tangible Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.67 -5.97 -3.56 -4.55 -4.11

Competitive Comparison of Aytu BioPharma's Tangible Book per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Aytu BioPharma's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aytu BioPharma's Price-to-Tangible-Book Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aytu BioPharma's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Aytu BioPharma's Price-to-Tangible-Book falls into.



Aytu BioPharma Tangible Book per Share Calculation

Aytu BioPharma's Tangible Book Value Per Share for the fiscal year that ended in Jun. 2023 is calculated as

Tangible Book Value per Share=(Total Stockholders Equity-Preferred Stock-Intangible Assets)/Shares Outstanding (EOP)
=(39.357-0-58.97)/5.51717
=-3.55

Aytu BioPharma's Tangible Book Value Per Share for the quarter that ended in Dec. 2023 is calculated as

Tangible Book Value per Share=(Total Stockholders Equity-Preferred Stock-Intangible Assets)/Shares Outstanding (EOP)
=(32.853-0-55.711)/5.56735
=-4.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total equity is a balance sheet item and equal to total assets less total liabilities of the company. Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.


Aytu BioPharma  (NAS:AYTU) Tangible Book per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Aytu BioPharma Tangible Book per Share Related Terms

Thank you for viewing the detailed overview of Aytu BioPharma's Tangible Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Aytu BioPharma (Aytu BioPharma) Business Description

Traded in Other Exchanges
Address
7900 East Union Avenue, Suite 920, Denver, CO, USA, 80237
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complimentary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. AR101/enzastaurin has received Orphan Drug designation from the FDA. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which it generates maximum revenue from the Rx segment.
Executives
Christopher Brooke officer: Chief Operating Officer C/O AYTU BIOPHARMA, INC., 373 INVERNESS PARKWAY, SUITE 206, ENGLEWOOD CO 80112
Jarrett Disbrow officer: Chief Business Officer 373 INVERNESS PARKWAY, SUITE 200, ENGLEWOOD CO 80112
John Jr. Donofrio director C/O AYTU BIOSCIENCE, INC., 373 INVERNESS PARKWAY, SUITE 200, ENGLEWOOD CO 80112
Carl Dockery director P.O. BOX 2477, LAKELAND FL 33806-2477
Vivian H Liu director
Mark K Oki officer: Chief Financial Officer C/O ALEXZA PHARMACEUTICALS INC, 2091 STIERLIN COURT, MOUNTAIN VIEW CA 94043
Joshua R. Disbrow director, officer: Chief Executive Officer AMPIO PHARMACEUTICALS, INC., 5445 DTC PARKWAY, SUITE 925, GREENWOOD VILLAGE CO 80111
Abhinav Jain director C/O AYTU BIOPHARMA, INC., 373 INVERNESS PARKWAY, SUITE 206, ENGLEWOOD CO 80112
Wilmot B. Harkey 10 percent owner C/O NANTAHALA CAPITAL MANAGEMENT, LLC, 130 MAIN ST. 2ND FLOOR, NEW CANAAN CT 06840
Daniel Mack 10 percent owner C/O NANTAHALA CAPITAL MANAGEMENT, LLC, 130 MAIN ST. 2ND FLOOR, NEW CANAAN CT 06840
Nantahala Capital Management, Llc 10 percent owner 130 MAIN ST., 2ND FLOOR, NEW CANAAN CT 06840
Greg Pyszczymuka officer: Chief Commerical Officer C/O AYTU BIOPHARMA, INC., 373 INVERNESS PARKWAY, SUITE 206, ENGLEWOOD CO 80112
Richard I Eisenstadt officer: Chief Financial Officer 4819 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Gerald W. Mclaughlin director 227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428
Beth Hecht director C/O NEOS THERAPEUTICS, INC., 2940 N. HIGHWAY 360, GRAND PRAIRIE TX 75050